Non-viral Expression of Mouse Oct4, Sox2, and Klf4 Transcription Factors Efficiently Reprograms Tadpole Muscle Fibers *in Vivo******□**^S**

Received for publication, November 23, 2011, and in revised form, December 28, 2011 Published, JBC Papers in Press, January 9, 2012, DOI 10.1074/jbc.M111.324368

Céline Vivien¹ **, Pierluigi Scerbo**1,2**, Fabrice Girardot, Karine Le Blay, Barbara A. Demeneix**3,4**, and Laurent Coen**3,5 *From the Unite´ Mixte de Recherche CNRS 7221, Évolution des Régulations Endocriniennes, Département Régulations Développement et Diversité Moléculaire, Muséum National d'Histoire Naturelle, 75231 Paris, France*

Background: Non-viral generation of induced pluripotent stem cells (iPSCs) *in vitro* is generally of low efficiency. **Results:** *In vivo* expression of non-integrated transgenes Oct4, Sox2, and Klf4 efficiently reprograms muscle cells. **Conclusion:** Reprogrammed, undifferentiated cells can be reliably and rapidly produced using naked DNA, exploiting synergy between muscle repair and reprogramming.

Significance: *In vivo* approach throws light on the molecular networks underlying reprogramming, suggesting alternate iPSC generation strategies.

Adult mammalian cells can be reprogrammed into induced pluripotent stem cells (iPSCs) by a limited combination of transcription factors. To date, most current iPSC generation protocols rely on viral vector usage *in vitro***, using cells removed from their physiological context. Such protocols are hindered by low derivation efficiency and risks associated with genome modifications of reprogrammed cells. Here, we reprogrammed cells in an** *in vivo* **context using non-viral somatic transgenesis in** *Xenopus***tadpole tail muscle, a setting that provides long term expression of non-integrated transgenes** *in vivo***. Expression of mouse** *mOct4***,** *mSox2***, and** *mKlf4* **(OSK) led rapidly and reliably to formation of proliferating cell clusters. These clusters displayed the principal hallmarks of pluripotency: alkaline phosphatase activity, up-regulation of key epigenetic and chromatin remodeling markers, and reexpression of endogenous pluripotent markers. Furthermore, these clusters were capable of differentiating into derivatives of the three germ layers** *in vitro* **and into neurons and muscle fibers** *in vivo***. As** *in situ* **reprogramming occurs along with muscle tissue repair, the data provide a link between these two processes and suggest that they act synergistically. Notably, every OSK injection resulted in cluster formation. We conclude that reprogramming is achievable in an anamniote model and propose that** *in vivo* **approaches could provide rapid and efficient alternative for non-viral iPSC production. The work opens new perspectives in basic stem cell research and in the longer term prospect of regenerative medicine protocols development.**

pluripotent stem cells $(iPSCs)^6$ via ectopic expression of the four transcription factors Oct4, Sox2, c-Myc, and Klf4 has revolutionized the concepts of pluripotency (1). Following this groundbreaking discovery, iPSCs have been generated in a number of mammalian species, from a wide range of different cell types with efficiencies depending on the differentiation status of the somatic cell source used (2, 3). To date, reprogramming to iPSC mainly relies on the use of retroviral delivery methods and is a gradual process occurring over 1–2 weeks *in* $vitro$ $(1, 4-6)$. However, the use of integrative viral vectors and c-Myc as a reprogramming factor is frequently associated with tumor formation in iPSC-derived chimeric mice (7). Attempts to overcome this problem, by elimination of c-Myc (8, 9) or by replacement of retroviruses with non-integrative vectors, including plasmids (2, 10–12), led to lower reprogramming efficiencies (12, 13).

The ability to reprogram differentiated cells into induced

Reversing terminally differentiated cells to pluripotency through reprogramming is not a new notion. It was first introduced in amphibians half a century ago when Sir J. Gurdon and his colleagues successfully cloned tadpoles from differentiated *Xenopus* cell nuclei transplanted into the cytoplasm of unfertilized eggs (14). Following this pioneering demonstration, nuclear reprogramming by somatic nuclear transfer has been achieved in many mammalian species (12, 15). More recently, reprogramming of mammalian nuclei to a pluripotent-like status by *Xenopus* oocyte cytoplasm demonstrated that the *Xenopus* oocyte can override the stability of mammalian cell differentiation (16). Nevertheless, whereas all vertebrates share pluripotency, most data on reprogramming comes from mammalian systems, mainly human and mouse. Moreover, the *in vitro* protocols used for iPSC generation do not take into account contexts that might impact on the reprogramming process and its efficiency at higher order levels (*e.g.* tissue, organ, system). Therefore, reprogramming approaches to gen-

^{*} This work was supported by European Union grant Crescendo and the French Programme National de Recherche sur les Perturbateurs Endocriniens program. □**^S** This article contains [supplemental Figs. S1–S8,](http://www.jbc.org/cgi/content/full/M111.324368/DC1) [Table S1,](http://www.jbc.org/cgi/content/full/M111.324368/DC1) [supplemental](http://www.jbc.org/cgi/content/full/M111.324368/DC1)

[Experimental Procedures,](http://www.jbc.org/cgi/content/full/M111.324368/DC1) and [additional references.](http://www.jbc.org/cgi/content/full/M111.324368/DC1)
¹ Both authors contributed equally to this work.

² Recipient of a Ph.D. grant from the French Ministry of Research.

³ Both authors are co-senior authors.

⁴ To whom correspondence may be addressed. Tel.: 33140793607; Fax: 33140793618; E-mail: bdem@mnhn.fr.
⁵ To whom correspondence may be addressed. Tel.: 33140795747; Fax:

^{33140793618;} E-mail: coen@mnhn.fr.

⁶ The abbreviations used are: iPSC, induced pluripotent stem cell; AP, alkaline phosphatase; dpi, days post-injection; OSK, mOct4, mSox2, and mKlf4; PFA, paraformaldehyde.

erate iPSCs *in vivo*, which remain poorly investigated, would allow to explore the influence of the native environment of the cells to be reprogrammed.

We exploited the experimental advantages of the *Xenopus* model to explore the ability to reprogram *Xenopus* differentiated cells *in vivo*. We used *in vivo* non-viral somatic transgenesis that allows long lasting gene expression in live tadpoles (17, 18). We showed that combined transfection of mouse mOct4, mSox2, and mKlf4 (OSK) into *Xenopus* tadpole tail muscle led to proliferative cell clusters formation. Cells in these clusters expressed typical hallmarks of pluripotency, such as reactivation of endogenous pluripotent markers, and showed the capacity to differentiate into derivatives of all three germ layers. *In vivo* reprogramming occurred in every tadpole transfected, probably being facilitated by simultaneous muscle repair. We conclude that reprogramming can be efficiently obtained by non-viral methods *in vivo* and that *Xenopus* reprogrammed cells share properties with mammalian iPSCs.

EXPERIMENTAL PROCEDURES

Animals—*Xenopus laevis* tadpoles were raised as described (18) and staged according to Nieuwkoop and Faber (19). Sacrifices and animal studies were conducted according to the principles and procedures described in Guidelines for Care and Use of Experimental Animals.

Plasmid Injections—Somatic gene transfer was carried out as described previously using perchlorated tadpoles at stage NF55 (18). In brief, 1 μ l of different plasmid mixes was injected intramuscularly at the concentrations indicated in the text. DNA constructs used were: peGFP-C1 (CMV-GFP) and pDsRed2-N1 (CMV-RFP) (Clontech); pGL3 (CMV-LUC) (Invitrogen); CMV-mOct4 and CMV-mSox2; SV40-LUC. Mouse *Klf4* cDNA was PCR-amplified and cloned in the pCMV-3FLAG plasmid (Sigma), giving CMV-mKlf4. Plasmids were purified using the QiaFilter kit (Qiagen). pCMV-3FLAG was used as an empty vector to equalize the DNA amount for each injection.

Immunohistochemistry—*In toto* GFP reporter expression was monitored on living tadpoles before further analyses. Before being processed for immunohistochemical analyses, cell cultures were PFA-fixed (4% in PBS for 10 min at 4 °C), and injected tail muscles were dissected, PFA-fixed (4% in PBS for 3 h at 4 °C), and sectioned using a cryostat (14 μ m). Immunodetection was carried out as described previously (20) on sections or fixed cell cultures, using the following primary antibodies: rabbit anti-phosphohistone H3 (1:300; Upstate Biotechnology), rabbit anti-active caspase 3 (1:250; BD Biosciences Pharmigen), rabbit anti- β -tubulin III (1:300; Sigma), mouse anti-MZ15 (1:500; DSHB), mouse anti-NCAM (1:300; DSHB), rabbit anti-mKlf4 (1:150; Santa Cruz Biotechnology), rabbit anti-mOct4 (1:400; Abcam), mouse anti-HA (1:100; Sigma), mouse anti-Pax7 (1:300; DSHB), rabbit anti-GFP (1:300; Invitrogen), and the appropriate secondary fluorescent antibodies (1:1500). 5-Bromo-2--deoxyuridine (BrdU) labeling was carried out using BrdU Labeling and Detection kit I (Roche Applied Science) following intraperitoneal injection of 2 μ l of BrdU (1 mg/ml) in NF55 perchlorated tadpoles every 2 days after transfection. Alkaline phosphatase activity was revealed using the

AM0100-1KT kit (Sigma). All sections were DAPI (4',6-diamidino-2-phenylindole)-counterstained and mounted in Moviol (Calbiochem) before observation under light and fluorescent microscopy.

Cell Culture—Cell cultures were derived from tadpole muscles at 7 or 12 days after transfection according to the previously reported protocol (21). Cells were cultured at 20 °C in 70% Leibovitz L-15 medium (Invitrogen) with $5\times$ serum replacement (Sigma) supplemented with antibiotic (Invitrogen). Treatments (3 or 5 days) were carried out with retinoic acid (1 μ M), recombinant mouse FGF-8b (50 ng/ml), recombinant mouse Noggin/Fc chimera (50 ng/ml), recombinant human/mouse/rat activin A (5, 50, or 100 ng/ml). All molecules were from R&D Systems, except retinoic acid (Sigma). Cultured cells were fixed with 4% PFA in PBS for 30 min at 4 °C, rinsed in PBS, and immunostained with corresponding antibodies, as described above.

Real-time Quantitative PCR Analyses—For each point monitored, RNA extractions were performed on three pooled muscle samples or trypsinized cell cultures. The protocol, primers, graphical representations, and statistical analyses are detailed in supplemental [Experimental Procedures](http://www.jbc.org/cgi/content/full/M111.324368/DC1) and [supplemental](http://www.jbc.org/cgi/content/full/M111.324368/DC1) [Table S1.](http://www.jbc.org/cgi/content/full/M111.324368/DC1)

Beads Transplanted in Muscle—Heparin-acrylic beads (Sigma) were incubated for 2.5 h at room temperature with FGF-8 (10 μ g/ml), Noggin (10 μ g/ml), or BSA 0.1% (Sigma), then washed in PBS. For each factor, one bead was implanted subcutaneously at 12 days post-injection (dpi) in each transfected myomere (see Fig. 1). After 5 days, muscles were fixed with 4% PFA in PBS for 3h at 4 °C, rinsed in PBS, then sectioned and immunostained with anti- β -tubulin III (1:300).

Xenopus Transgenic Lines—Transgenic animals were obtained according to the modified Kroll and Amaya protocol (22). In the pNanog-GFP transgenic line, GFP reporter expression is placed under the control of the promoter sequence [-332/+50] of the mouse pluripotency gene *mNanog* (23). In the pCar-GFP transgenic line, GFP reporter expression is placed under the control of the actin cardiac promoter, leading to a specific GFP expression in cardiac and skeletal muscle (24).

Graft Transplant—OSK injection was performed in perchlorated NF55-staged pCar-GFP transgenic tadpoles. At 10 dpi, injected muscles were dissected and placed in cold filtered PBS (pH 7.5). The muscle region containing clusters were dissected into 0.4 mm²-faced cubes and placed in cold L-15 medium, with $1\times$ serum replacement supplemented with antibiotic. Cubes were transplanted intramuscularly into perchlorated WT tadpoles at the same developmental stage (NF55). Two months later, tail muscles were fixed with 4% PFA in PBS for 3 h at 4 °C, rinsed in PBS, then cryosectioned (120 μ m), and floating sections were immunostained with rabbit anti-GFP (1:300) and mounted in Moviol before observation under fluorescent microscopy.

RESULTS

Clusters of Small Cells Appear in Tadpole Tail Muscle following Somatic Injection of Mouse OSK Factors—Non-integrative, non-viral, and non-replicative expression vectors encoding mouse OSK and/or GFP, all under the transcriptional control of

FIGURE 1. **Expression of mouse OSK factors in tadpole muscle leads to GFP loss and cell mass appearance.** *A*, somatic transgenesis in tadpole tail muscle of a GFP-reporter construct \pm mouse OSK (200 ng/ μ] per plasmid). GFP expression was monitored at 3, 7, 14, and 21 dpi, increasing in controls (*upper panels*) but decreasing at 7 dpi in OSK-injected muscles (*lower panels*; *arrowheads* indicate the same myomeric units). Experiments were performed 5 times (*n* 10 for each time point), providing similar results. *B*, 200-µm-thick slice from OSK muscle at 11 dpi revealing a large, dense cell mass. *C*, residual GFP-positive fiber (*) near the mass (*arrowhead*). *Scale bars*, 500 μ m.

the CMV promoter, were injected in *Xenopus* pre-metamorphic tadpole tail muscles at various doses (see "Experimental Procedures," Fig. 1*A*, and [supplemental Fig. S1](http://www.jbc.org/cgi/content/full/M111.324368/DC1) for optimization experiments). This "naked" DNA-based gene delivery method is known to specifically transfect muscle fibers without integration (25) and, in that way, is used for human vaccination (26). The conditions used in somatic injection experiments yielded an average of 25 transfected muscle fibers per injected tadpole as estimated by GFP expression (data not shown). Three dpi, GFP was detectable only in differentiated muscle fibers of both OSK-injected and control animals. However, the GFP-expressing fibers were rapidly lost in OSK-transfected muscles concomitantly with the appearance of large, dense cell clusters (Fig. 1, *B* and *C*).

Clusters occurred at all tested plasmid concentrations (100, 200, and 400 ng/ μ l; Fig. 2, A–C and E –G), many filling the space previously occupied by a lost GFP-expressing fiber [\(supple](http://www.jbc.org/cgi/content/full/M111.324368/DC1)[mental Fig. S2,](http://www.jbc.org/cgi/content/full/M111.324368/DC1)*A*–*C*). OSK-injected tadpoles frequently showed several clusters in the transfected area (Fig. 2, *A*–*C* and clearly seen in [supplemental Fig. S2](http://www.jbc.org/cgi/content/full/M111.324368/DC1)*A*). Furthermore, nuclei in the area surrounding the site of OSK injection were disorganized, contrasting with the regular nuclear distribution of GFP-injected control muscles (compare Fig. 2*D* and [supplemental Fig. S2](http://www.jbc.org/cgi/content/full/M111.324368/DC1)*D*). This disorganized nuclear distribution also clearly differed from that of apoptotic muscle fibers [\(supplemental Fig. S2,](http://www.jbc.org/cgi/content/full/M111.324368/DC1) *E* [and](http://www.jbc.org/cgi/content/full/M111.324368/DC1) *F*), frequently seen following somatic transfection in muscle (18). Nuclei morphology also differed, with large nuclei present in intact fibers (Fig. 2*H*) and 2–3 times smaller nuclei in clusters (Fig. 2*I*). Using 200 ng/ μ l plasmid-injected concentration, the clusters were observed in 30% of OSK-transfected tadpoles at 3 dpi and in 100% at 7 dpi (Fig. 2*J*); at 21 dpi, smaller clusters were still observable in 20% of injected animals. Clusters never formed in control GFP-injected tadpoles (Fig. 2, *D* and *J*). Notably, cell clusters were also observed in muscles injected with individual transcription factors (O, S, or K alone); however, clusters were fewer than with OSK injection [\(supple](http://www.jbc.org/cgi/content/full/M111.324368/DC1)[mental Fig. S3\)](http://www.jbc.org/cgi/content/full/M111.324368/DC1). As 200 ng/ μ l OSK injection gave optimal cluster formation (Fig. 2*J*), this plasmid concentration was used in all following experiments.

Expression of the Three Mouse Factors OSK Decreases Over Time—Given that mouse transcription factors were used, their expression can be followed unambiguously, unhampered by putative endogenous expression of the *Xenopus* homologues. Expression of exogenous reprogramming factors in OSK-transfected tadpoles was high at 3 and 7 dpi, then decreased strongly

FIGURE 2. **Cell cluster formation is dose- and time-dependent.** *A*–*D*, nuclei, observed by DAPI-staining, are grouped in OSK clusters at 7 dpi (A, 100 ng/ μ l; B , 200 ng/ μ l; *C*, 400 ng/ μ l for each plasmid), whereas muscle fibers show normal peripheral nuclear organization in GFP-controls (*D*). *E*–*G*, representative clusters surround neighboring muscle fibers at 7, 14, and 21 dpi for the 200 ng/ μ l condition. *H* and *I*, magnifications show large nuclei in control fibers (*H*), whereas nuclei in OSK clusters are smaller (*I*). *J*, kinetics of cluster occurrence for GFP-controls and OSK-injected muscles shown at the 3 concentrations. For each point, independent $4 \le n \le 9$ samples were pooled and the percentage of cluster-containing muscles calculated. *Scale bars*, 100 μ m (*A*–*G*), 20 m (*H*–*I*).

between 7 and 14 dpi, and was virtually undetectable by 21 dpi [\(supplemental Fig. S4](http://www.jbc.org/cgi/content/full/M111.324368/DC1)*A*). Immunodetection revealed that, in OSK-transfected tadpoles, mouse proteins were detected in

FIGURE 3. **Cell clusters are proliferative and express endogenous pluripotency markers.** Using PH3-antibody (*A* and *B*) and BrdU labeling (*C*- and *D*-), cell proliferation was compared at 14 dpi between GFP (A) or RFP (*C* and *C'*) controls and OSK-injected muscles (*B*, *D*, and *D'*). PH3-positive cells (*B*) and strong BrdU labeling (*D*-) occurred in OSK clusters, but not in controls (*A* and *C*-). Note that BrdU labeling shows similar proliferative status of epidermis (*Ep*) in both conditions. Apoptosis was followed using active caspase 3 antibody in OSK-transfected muscles at 14 dpi (*E* and *F*) and 21 dpi (*G*), showing an increase of apoptotic cells in clusters. AP activity was strong in OSK-injected muscles at 14 dpi and co-localized with DAPI-positive clusters (*I* and *I*-, *arrows*), whereas GFP-controls (G and G') showed no AP labeling except in blood vessels (bv). Each labeling was performed ≥3 times. *Scale bars,* 100 µm (A–*E* and *H–I'*); 50 µm (F and G). J, expression of xtert, brg1, and gadd45a (epigenetic and chromatin-remodeling markers) and nr5a2, xoct91, gdf3, xsox3, xsox2, and xventx2 (pluripotencyfactors) at 3, 7, 14, and 21 dpi in GFP-controls(*green boxes*) and OSK-transfectedmuscles(*red boxes*), using real-time quantitative PCR. For each gene, basal levels in non-injected muscles are indicated (WT, black boxes) and absence of transcript noted as Φ . Samples were from independent experiments, with three muscles pooled per sample (4 ≤ n ≤ 8 samples per group). mRNA levels were expressed as relative to WT except when expression was not detected, then mRNA levels were expressed as relative to the first value observed for OSK. *Boxes* represent minimum and maximum values around the median. Nonparametric Mann-Whitney *U* test was used to assess statistical differences *versus* WT, except when indicated by *black bars*: **, *p* 0.01; *, *p* 0.05. *K*, schematic representation of the protocol used in reprogramming experiment performed with the pNanog-GFP transgenic tadpoles. *L* and *M*, GFP immunolabeling of a pNanog-GFP transgenic *Xenopus* tadpole injected with OSK shows a strong and specific GFP expression in clusters (*cl*) at 7 dpi, whereas muscle fibers (*m* and *) are GFP-negative. *Scale bars*, 100 m (*K*–*L*).

nuclei of GFP-positive fibers at 7 dpi, but not in cluster cells nuclei [\(supplemental Fig. S4,](http://www.jbc.org/cgi/content/full/M111.324368/DC1) *B*–*F*). Furthermore, all mOct4 positive nuclei were Pax7-negative, implying that satellite cells are not transfected following OSK injection [\(supplemental Fig.](http://www.jbc.org/cgi/content/full/M111.324368/DC1) [S4](http://www.jbc.org/cgi/content/full/M111.324368/DC1)*G*).

Cell Clusters Are Proliferative and Reexpress Pluripotent Marker Alkaline Phosphatase—The proliferative status of clusters was analyzed using the mitotic marker PH3 and BrdU labeling. At 14 dpi, clusters contained numerous PH3-positive cells (Fig. 3*B*) whereas no PH3 signal was seen in GFP-controls

(Fig. 3*A*) or in non-injected tadpole muscle (data not shown). BrdU labeling showed high numbers of labeled cells in clusters at 14 dpi (Fig. 3, *D* and *D'*), confirming their proliferative nature. In GFP-controls, only rare BrdU-positive cells were detected in the injected area (Fig. 3, *C* and *C*-). As expected, epidermal BrdU incorporation was similar in OSK and GFPcontrol tadpoles (Fig. 3, C' and D'). Clusters proliferated up to 14 dpi. At 21 dpi, when cluster size decreased, PH3 labeling was lost concomitantly with an increase of caspase 3-positive cells, suggesting that apoptosis might be involved in cluster reduction (Fig. 3, *E*–*G*).

Alkaline phosphatase (AP) activity, routinely used as a pluripotency marker for embryonic stem cells (ESCs) and iPSCs (27), was strongly detected in OSK clusters (Fig. 3, I and I'). No AP activity was observed in GFP-controls (Fig. 3, *H* and *H*-), except in blood vessels, which are known to be AP-positive (28). AP expression suggests a return to an undifferentiated state. To assess further this possibility, reactivation of a pluripotency program in OSK-injected muscles was evaluated using different markers.

Xenopus Pluripotency Genes Are Reactivated in OSK-injected Tadpoles—Following injection, myogenic markers were similarly reactivated in GFP-controls and OSK-injected muscles [\(supplemental Fig. S5\)](http://www.jbc.org/cgi/content/full/M111.324368/DC1); however, significant differences were observed for endogenous homologues of mammalian markers of pluripotency (Fig. 3*J*). Notably, OSK-injected muscle showed specific activation of *xoct91*, the functional homologue of mammalian *Oct4* (29), of *nr5a2*, a regulator of *Oct4* expression in pluripotency (30), and of *gdf3*, a TGF-β family member involved in regulation of the pluripotent state (31) and in iPSCs reprogramming (32, 33). As for *xoct91*, *gdf3* expression was specific to OSK-injected muscles and maintained for 3 weeks. Expression of *xsox2* and *xsox3,*two genes related to mammalian *Sox2* (34), was significantly down-regulated in GFP-controls and up-regulated in OSK-injected tadpoles as the reprogramming process progressed. We also examined reactivation of *xventx2*, previously described as expressed in multipotent stem cells in *Xenopus* (35) and proposed to share a functional relationship with Nanog (36).⁷ As for *xoct91*, *xventx2* was precociously activated in OSK samples. *xventx2* expression was totally down-regulated at 14 dpi, suggesting that reprogrammed cells at this time might be responsive to differentiation cues. Intriguingly, we observed reexpression of *xventx2* in both OSK and GFP-control muscles at 21 dpi, suggesting an unknown role for this factor during late muscle repair.

To validate further the establishment of a transcriptional state similar to that of mammalian pluripotent cells in these clusters, a transgenic *Xenopus* line expressing GFP under the promoter of the mouse pluripotency factor *mNanog* (pNanog-GFP) was used. Similar readouts, using transgenic cell lines expressing GFP under the control of either the *Oct4* or the *Nanog* promoters (7, 11, 37–39), are commonly used in mammalian systems to define whether cultured somatic cells transfected with reprogramming factors have reached full iPSC (*i.e.*

pluripotent) status. Thus, using pNanog-GFP transgenic tadpoles, the OSK plasmid mix was injected into the muscle without the CMV-GFP construct. In this case, GFP expression therefore reflected activation of the mouse *Nanog* promoter integrated in the genome. As shown in Fig. 3*L*, OSK injection resulted in GFP expression specifically in clusters, but not in non-transfected muscle cells.

Epigenetic Factors Are Up-regulated in OSK-reprogrammed Cells—Reprogramming is facilitated if epigenetic switches and chromatin remodeling are activated (40, 41). We thus monitored expression of *brg1* and *gadd45a*, two factors essential for nuclear reprogramming in *Xenopus* (42, 43), and that show, respectively, a key role in chromatin remodeling and in active DNA demethylation. Both factors were detectable in uninjected (WT) muscle but were specifically up-regulated in OSKinjected muscles (Fig. 3*J*). Reactivation of *brg1* expression was observed from 14 dpi in GFP-controls and might be involved in MyoD-mediated differentiation during muscle repair (44). Telomerase activity induction is another important feature of iPSCs (45). Expression of the telomerase reverse transcriptase gene (*xtert*) was markedly increased in OSK samples (Fig. 3*J*). Altogether, activation of *brg1*, *gadd45a*, and *xtert* suggests that epigenetic changes occurred in OSK-injected muscles, favoring reprogramming.

OSK-reprogrammed Cells Differentiate in Vitro into Derivatives of Three Germ Layers—GFP-control or OSK-injected muscles were cultured to test their differentiative potential [\(supplemental Fig. S6](http://www.jbc.org/cgi/content/full/M111.324368/DC1)*A*). After 24 h, only in OSK-derived cultures we observed the presence of AP-positive clones with characteristic ESC-like morphology [\(supplemental Fig. S6,](http://www.jbc.org/cgi/content/full/M111.324368/DC1) *B***–***[H](http://www.jbc.org/cgi/content/full/M111.324368/DC1)*). When cultured for 5 days in normal medium these clones progressively acquired various differentiated morphologies [\(supplemental Fig. S7\)](http://www.jbc.org/cgi/content/full/M111.324368/DC1), suggesting spontaneous differentiation.

OSK-derived cultures were then treated with different factors to induce differentiation. FGF-8 $+$ Noggin treatments (46) resulted in differentiation toward a neurectodermal fate (Fig. 4, A –*C*). Retinoic acid with FGF-8 $+$ Noggin induced differentiated neurons (Fig. 4*A*). No neuronal differentiation was seen in similarly treated GFP-control cultures. To differentiate OSKderived cells toward a mesodermal fate, low activin concentrations were used (47). Colonies and individual cells labeled with the MZ15 antibody that recognizes mesodermal-derived notochord cells were obtained (Fig. 4, *D-*-*F*), indicating that OSKderived cells can give rise to cells with a different mesodermal precursor origin from that of muscle. Finally, we used Noggin and high doses of activin, known to promote endodermal differentiation of *Xenopus* animal caps (47). Real-time quantitative PCR was used to monitor the expression of endodermal specification markers*sox17*, *gata6*, *cerberus*, and *hhex* (Fig. 4*G*). These markers were weakly expressed or absent from controls. In contrast, *gata6*, *cerberus*, and *hhex* mRNAs increased significantly in non-treated OSK-derived cultures, suggesting that spontaneous differentiation to endoderm occurred. In treated cells, *sox17* and *cerberus* increased significantly, demonstrating enhanced endodermal differentiation. The mesodermal marker *myf5* was down-regulated by high dose activin, favoring an endodermal fate [\(supplemental Fig. S8\)](http://www.jbc.org/cgi/content/full/M111.324368/DC1). Furthermore, sponta-

⁷ P. Scerbo, F. Girardot, C. Vivien, G. V. Markov, G. Luxardi, B. A. Demeneix, L. Kodjabachian, and L. Coen, unpublished data.

FIGURE 4. **OSK-reprogrammed cells can differentiate into derivates of the three embryonic lineages** *in vitro* **and into neurons and muscles** *in vivo***.** *A*–*C*, neuroectodermal differentiation with FGF-8 + Noggin + retinoic acid (A) or FGF-8 + Noggin (*B* and *C*) treatment of 12 dpi OSK-derived cultures, shows tubulin III labeled neurons after 5 days (*A* and *B*), and NCAM-positive cells at 3 days (*C*). *D*–*F*, mesodermal differentiation was obtained with low activin treatment of 12 dpi OSK-derived cultures and revealed with a notochord (MZ15) antibody, showing MZ15-positive cells after 3 days (*D*, activin 5 ng/ml), or individual labeled cells at 3 days (*F*, activin 50 ng/ml) or 5 days (*E*, activin 5 ng/ml). *G*, endodermal differentiation was obtained with high activin (100 ng/ml) Noggin treatments of 12 dpi OSK-derived cultures and revealed by real-time quantitative PCR using endodermal markers (*sox17*, *gata6*, *cerberus*, and *hhex*). After 3 days, spontaneous as well as induced endoderm induction was observed in non-treated (*OSK*) and treated (*OSKA*) cultures, but not in 12 dpi GFP-control cultures (*GFP* and GFP⁺A). Treatments were performed >6 times. Quantitative PCR data are represented as described in Fig. 3 and mRNA levels expressed as relative to control cultures (GFP): *, $p < 0.05$; not significant (*ns*) $p > 0.1$. *H* and *I*, OSK-injected muscles labeled with anti-tubulin III antibody at 14 dpi showed spontaneous neuronal differentiation in cell clusters (*H*). I, differentiated neuron, with axonal network (*arrows*) and its cell body (*arrowhead* indicates nucleus), was obtained following 5 days treatment of 12 dpi OSK-injected tadpoles with FGF-8 + Noggin. *J*, schematic represents transplant protocol used to follow reprogrammed cellfate reversion in muscle tissue. OSK was injected in a pCar-GFP transgenic tadpole, at 10 dpi the reprogrammed cells were transplanted in a WT tadpole, and the muscle of grafted tadpoles was observed 2 months later. *K* and*L*, two examples of grafted tadpoles show the presence of numerous(*K*) and at a lesser extent (*L*, *arrows*) GFP-positive muscle fibers, indicating the reversion of pCar-GFP reprogrammed cells toward a muscle fiber phenotype after transplantation. *Scale bars*, 50 μ m (A–D), 10 μ m (*E* and *F*), 25 μ m (*H* and *I*), 100 μ m (*K* and *L*).

neous mesodermal and neurectodermal differentiation was revealed using the *xnot* and *xsox2* markers, respectively [\(sup](http://www.jbc.org/cgi/content/full/M111.324368/DC1)[plemental Fig. S8\)](http://www.jbc.org/cgi/content/full/M111.324368/DC1). Thus, OSK cultures can differentiate spontaneously into the three germ layers, and activin can enhance endoderm differentiation.

Xenopus-iPS Cells Differentiate into Neuronal and Muscle Phenotypes in Vivo—Teratoma formation is another stringent method for assessing iPSC pluripotency (27). We explored the possibility that *Xenopus*-reprogrammed cells in clusters share the ability to differentiate toward non-mesodermal derivatives directly *in vivo*. We observed neurons within OSK-induced clusters (Fig. 4*H*), showing that spontaneous neurectodermal differentiation occurs*in vivo*. Furthermore, when neurectodermal differentiation *in vivo* was forced by FGF-8 $+$ Noggin treat-

ment, large and fully differentiated neurons were observed within muscle (Fig. 4*I*). No neurons were induced when treating GFP-control muscle.

Using a transplant protocol, we also demonstrated that OSKreprogrammed cells retain the ability to redifferentiate into muscle fibers. Indeed, pCar-GFP transgenic tadpoles were injected with OSK and at 10 dpi, dissected pieces of tissue containing the reprogrammed cells were transplanted into WT non-transgenic tadpoles. Two months later, we observed the presence of GFP-positive fibers in tails of transplanted tadpoles, their origin necessarily arising from reprogrammed fibers of pCar-GFP animals (Fig. 4, *J*–*L*). Conversely, as a control, when the graft originated from pCar-GFP tadpoles injected with the pCMV-3FLAG empty vector instead of the reprogramming

FIGURE 5. **Generation of** *Xenopus***-iPS-like cells** *in vivo***.** Model for *in vivo* non-viral induction of *Xenopus* reprogrammed cells is shown. Following coinjection of mOSK with a GFP-reporter in tadpole tail (mOSK+GFP), GFPtransfected fibers (in *green*) dedifferentiate into proliferative undifferentiated *Xenopus* iPS-like cells (in *blue*). Reprogrammed cells of mesodermal origin possess an increased developmental potential, differentiating *in vitro* toward derivatives of the three embryonic lineages and into neurons and muscle fibers*in vivo*.

factors, no GFP-expressing fibers were observed in transplanted WT tadpoles.

DISCUSSION

A fundamental goal in stem cell biology is to understand better the regulation of the transcription factor networks that control pluripotent cell identity and fate decisions *in vivo*. This goal is related to the need to understand the capacity of a cell to reprogram in tissue- and stage-specific contexts. However, the mechanisms that favor or limit the reprogramming process are not well understood. For instance, most studies on iPSC reprogramming are performed *in vitro* and show that reprogramming efficiency depends mainly on the differentiation status of the cell source used (12, 48, 49), the cellular context greatly influencing factors required to generate iPSCs (50). In addition, one of the main aims of iPSC studies is to facilitate regenerative medicine, hence the importance of placing iPSC generation in a physiological perspective. Our hypothesis is that working in an *in vivo* context allows the physiological setting and higher order regulations to be taken into account. In our experiments we used the living *Xenopus* tadpole to explore the transcription factor-mediated reprogramming ability of differentiated cells *in vivo*.

Taken together, our findings show that reprogrammed cells can be obtained *in vivo* by ectopic expression of mouse *mOct4*, *mSox2*, and *mKlf4* in tadpole muscle (Fig. 5). Importantly, the gene delivery method used, naked DNA injection in muscle tissue, specifically transfects muscle fibers without integration of foreign DNA (25). Our laboratory has developed and used for decades such a technique in *Xenopus* (see for instance Refs. 17, 18), showing that transfection of muscular cell types other than

In Vivo Generation of Reprogrammed Cells in Muscle

fibers was not observed. Further, in the experiments described here, CMV-driven expression of GFP and of OSK was only detected in muscle fibers (Fig. 1 and [supplemental Fig. S1](http://www.jbc.org/cgi/content/full/M111.324368/DC1) and [Fig. S4\)](http://www.jbc.org/cgi/content/full/M111.324368/DC1) and was not detected in satellite cells [\(supplemental Fig.](http://www.jbc.org/cgi/content/full/M111.324368/DC1) [S4](http://www.jbc.org/cgi/content/full/M111.324368/DC1)*G*). The transfected fibers remained stable in GFP-controls, whereas they gradually disappeared from OSK-injected muscles (Fig. 1 and [supplemental Fig. S1\)](http://www.jbc.org/cgi/content/full/M111.324368/DC1) to be replaced by clusters of proliferative cells (Fig. 2 and Fig. 3, *A*–*D*, and [supplemental](http://www.jbc.org/cgi/content/full/M111.324368/DC1) [Fig. S2\)](http://www.jbc.org/cgi/content/full/M111.324368/DC1). Remarkably, each OSK-transfected muscle showed the formation of at least one cluster at 7 dpi (Fig. 2 and [supplemen](http://www.jbc.org/cgi/content/full/M111.324368/DC1)[tal Fig. S2\)](http://www.jbc.org/cgi/content/full/M111.324368/DC1), giving 100% efficiency in the generation of reprogrammed cells *in vivo*. We observed that cluster size increased up to 14 dpi and then decreased to be undetectable after 21 dpi (Fig. 2), at least in part involving apoptosis (Fig. 3, *E-*-*G*). The transient occurrence of cluster in muscle can be explained by the fact that the non-replicative and non-integrative plasmid vectors will be lost by dilution during cell division. Thus, the absence of further source of reprogramming factors after 14 days [\(supplemental Fig. S4\)](http://www.jbc.org/cgi/content/full/M111.324368/DC1) will no longer support cluster formation in muscle. Indeed, the reprogrammed cells at this time will be responsive to differentiation cues, particularly those of muscle tissue, as shown by muscle redifferentiation of reprogrammed cells after transplant (Fig. 4, *J*–*L*).

Four arguments demonstrate that OSK-injected muscle contain reprogrammed cells with properties reminiscent to that frequently reported for iPSC generated in mammals. First, clusters contain AP-positive cells (Fig. 3*I*), a pluripotent marker currently used to identify ESCs or iPSCs (27). Second, three *bona fide* markers of reprogramming are specifically expressed in OSK-transfected muscle: *xoct91*, *xventx2*, and *gdf3* (Fig. 3*J*). In particular, *xoct91* and *xventx2* are, respectively, the functional homologues of $Oct4$ (29) and Nanog (35, 36), \prime reactivation of which in iPSCs are common readouts (37–39) to identify mammalian reprogrammed cells, and considered by some as a "gold standard" (27). Indeed, *xoct91* and *xventx2* reexpression could distinguish pluripotent *versus* differentiated cells in *Xenopus* tadpoles and thus represent *bona fide* markers of reprogramming in this model. Third, activation of the epigenetic modifiers *brg1*, *gadd45a*, and *xtert* (Fig. 3*J*) could confer epigenetic plasticity to OSK-injected muscles, enhancing reprogramming, as seen by overexpression of *Brg1* in mouse fibroblasts (41). Finally, the reprogrammed cells can differentiate into derivatives of the three germ layers*in vitro* (Fig. 4,*A*–*G*, and [supplemental Fig. S7](http://www.jbc.org/cgi/content/full/M111.324368/DC1) and [Fig. S8\)](http://www.jbc.org/cgi/content/full/M111.324368/DC1) and *in vivo* into muscle fibers (Fig. 4, *J*–*L*), as well as neurons, thus contributing to production of cell lineages other than the original mesodermal muscle (Fig. 4, *H*–*I*). In line with these observations, we show that the mouse *Nanog* promoter is activated in cell clusters (Fig. 3*L*), as previously observed in mammalian nuclei reprogrammed either by transcription factors or *Xenopus* oocyte extract (7, 11). Together, these findings strongly argue for a pluripotent status of the reprogrammed cells present in OSKgenerated clusters.

In our experiments, myogenesis was reactivated in response to injection injury. A rapid down-regulation of *myoD* expression was observed [\(supplemental Fig. S5\)](http://www.jbc.org/cgi/content/full/M111.324368/DC1). Recent findings show that suppression of *MyoD* expression by Oct4 is required to initiate the iPSC reprogramming from mouse myoblasts in cul-

ture (51). Thus, in our experiments, decreased *myoD* could catalyze reprogramming in OSK-transfected muscle cells. Cell division can also accelerate iPSC formation (52). During amphibian tail regeneration, dedifferentiation of injured fibers has been reported to support the muscle repair process. Interestingly, muscle dedifferentiation leads to cell cycle reactivation, polynucleated fiber fragmentation into mononucleated cells, and proliferation (53). In our*in vivo* model, a similar process involving dedifferentiation should occur during muscle repair in response to injection injury, and cell proliferation could contribute to reprogramming efficiency. The data thus show that reprogramming factors might synergize with the repair process to generate reprogrammed cells *in vivo*.

Two further observations bolster the argument that in injected muscle the repair process enhances reprogramming. First, injection of each mouse reprogramming factor separately also induced cluster formation, but at a lower frequency [\(sup](http://www.jbc.org/cgi/content/full/M111.324368/DC1)[plemental Fig. S3\)](http://www.jbc.org/cgi/content/full/M111.324368/DC1). Therefore, as for neural stem cells, which can be reprogrammed using *Oct4* alone (54), we suggest that factors present in*Xenopus*tadpole muscle facilitate reprogramming. Second, pluripotent-related genes *xsox2*, *xsox3*, *nr5a2* (Fig. 3*J*), or *xoct25* and *foxD3* (data not shown) are expressed in uninjected tadpole muscle, a feature arguing for a privileged ground state to reprogramming that could exist in muscle.

Nuclear transplantation of mammalian somatic nuclei into amphibian oocytes induces transcriptional reactivation of *Oct4*, *Sox2*, and *Nanog*, demonstrating that *Xenopus* oocyte determinants can trigger dedifferentiation of adult mouse nuclei (55). Reciprocally, here we demonstrate that mammalian factors can reprogram *Xenopus*somatic cells to generate undifferentiated *Xenopus* cells (Fig. 5), demonstrating that transcription factor-mediated reprogramming can be induced in groups as distant as mammals and amphibians. These data underline the usefulness of the *Xenopus* model for deciphering pluripotency and point to conserved fundamental principles for the regulatory gene networks known to control pluripotency in vertebrates. This notion is reinforced by the observation that the *Xenopus* Pou5f1 factors (xoct25, xoct91, and xoct60) can maintain pluripotency in mouse Oct4-deficient ESCs, and reciprocally mOct4 can rescue *Xenopus* Pou5f1s knocked-down embryos (29).

In conclusion, we show that *Xenopus* muscle is amenable to transcription factor-mediated reprogramming *in vivo*, yielding cells that seem comparable with Yamanaka's iPSCs (1). However, we cannot exclude that our reprogrammed cells have not reached the so-called "ground state pluripotency" because we did not verify germ line competence. One might wonder whether ground state pluripotency is achievable in *Xenopus* because germ line establishment relies on germ plasm in this organism (56). Nevertheless, our data unambiguously demonstrate that *in vivo* reprogrammed *Xenopus* cells have reached a "somatically primed" pluripotent state as recently defined by Johnson *et al.* (56). Therefore, we provide two entirely original demonstrations: first, that induced reprogramming can be achieved in an anamniote model and second, reprogrammed cells can be produced in an *in vivo* context without viral vectors. The fact that reprogramming can be induced and studied in a versatile developmental model could provide new leads for

translational research. Furthermore, the finding that reprogramming is facilitated by repair could open new perspectives in basic stem cell research and regenerative medicine.

Acknowledgments—We thank G. Levi and L. Kodjabachian for constructive criticism of the manuscript, F. Ishikawa (Kyoto University, Japan) for providing the CMV-mOct4 and CMV-mSox2 plasmids, A. Nishikawa (Shimane University, Japan) for providing the cell culture protocol, L. Sachs for providing SV40-LUC, A. Mazabraud (CNRS UMR 8080, France) for providing the pCar-GFP transgenic line, G. Benisti and J.P. Chaumeil for Xenopus breeding and care.

REFERENCES

- 1. Takahashi, K., and Yamanaka, S. (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* **126,** 663–676
- 2. Ho, R., Chronis, C., and Plath, K. (2011) Mechanistic insights into reprogramming to induced pluripotency. *J. Cell. Physiol.* **226,** 868–878
- 3. Tan, K. Y., Eminli, S., Hettmer, S., Hochedlinger, K., and Wagers, A. J. (2011) Efficient generation of iPS cells from skeletal muscle stem cells. *PLoS One* **6,** e26406
- 4. Jaenisch, R., and Young, R. (2008) Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming. *Cell* **132,** 567–582
- 5. Stadtfeld, M., and Hochedlinger, K. (2010) Induced pluripotency: history, mechanisms, and applications. *Genes Dev.* **24,** 2239–2263
- 6. Yamanaka, S., and Blau, H. M. (2010) Nuclear reprogramming to a pluripotent state by three approaches. *Nature* **465,** 704–712
- 7. Okita, K., Ichisaka, T., and Yamanaka, S. (2007) Generation of germ linecompetent induced pluripotent stem cells. *Nature* **448,** 313–317
- 8. Nakagawa, M., Koyanagi, M., Tanabe, K., Takahashi, K., Ichisaka, T., Aoi, T., Okita, K., Mochiduki, Y., Takizawa, N., and Yamanaka, S. (2008) Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. *Nat. Biotechnol.* **26,** 101–106
- 9. Wernig, M., Meissner, A., Cassady, J. P., and Jaenisch, R. (2008) c-Myc is dispensable for direct reprogramming of mouse fibroblasts. *Cell Stem Cell* **2,** 10–12
- 10. Okita, K., Hong, H., Takahashi, K., and Yamanaka, S. (2010) Generation of mouse-induced pluripotent stem cells with plasmid vectors. *Nat. Protoc.* **5,** 418–428
- 11. Okita, K., Nakagawa, M., Hyenjong, H., Ichisaka, T., and Yamanaka, S. (2008) Generation of mouse induced pluripotent stem cells without viral vectors. *Science* **322,** 949–953
- 12. Okita, K., and Yamanaka, S. (2011) Induced pluripotent stem cells: opportunities and challenges. *Philos. Trans. R Soc. Lond. B Biol. Sci.* **366,** 2198–2207
- 13. Hayden, E. C. (2011) Stem cells: The growing pains of pluripotency. *Nature* **473,** 272–274
- 14. Gurdon, J. B. (2006) From nuclear transfer to nuclear reprogramming: the reversal of cell differentiation. *Annu. Rev. Cell Dev. Biol.* **22,** 1–22
- 15. Hochedlinger, K., and Jaenisch, R. (2006) Nuclear reprogramming and pluripotency. *Nature* **441,** 1061–1067
- 16. Gurdon, J. B., and Melton, D. A. (2008) Nuclear reprogramming in cells. *Science* **322,** 1811–1815
- 17. de Luze, A., Sachs, L., and Demeneix, B. (1993) Thyroid hormone-dependent transcriptional regulation of exogenous genes transferred into *Xenopus* tadpole muscle *in vivo*. *Proc. Natl. Acad. Sci. U.S.A.* **90,** 7322–7326
- 18. Rowe, I., Le Blay, K., Du Pasquier, D., Palmier, K., Levi, G., Demeneix, B., and Coen, L. (2005) Apoptosis of tail muscle during amphibian metamorphosis involves a caspase 9-dependent mechanism. *Dev. Dyn.* **233,** 76–87
- 19. Nieuwkoop, P. D., and Faber, J. (1994) *Normal Table of Xenopus laevis (Daudin): A Systematical and Chronological Survey of the Development from the Fertilized Egg till the End of Metamorphosis*, Garland Publishing, New York
- 20. Coen, L., Le Blay, K., Rowe, I., and Demeneix, B. A. (2007) Caspase-9 regulates apoptosis/proliferation balance during metamorphic brain re-

modeling in Xenopus. *Proc. Natl. Acad. Sci. U.S.A.* **104,** 8502–8507

- 21. Shibota, Y., Kaneko, Y., Kuroda, M., and Nishikawa, A. (2000) Larval-toadult conversion of a myogenic system in the frog, *Xenopus laevis*, by larval-type myoblast-specific control of cell division, cell differentiation, and programmed cell death by triiodo-L-thyronine. *Differentiation* **66,** 227–238
- 22. Coen, L., du Pasquier, D., Le Mevel, S., Brown, S., Tata, J., Mazabraud, A., and Demeneix, B. A. (2001) *Xenopus* Bcl-X(L) selectively protects Rohon-Beard neurons from metamorphic degeneration. *Proc. Natl. Acad. Sci. U.S.A.* **98,** 7869–7874
- 23. Kuroda, T., Tada, M., Kubota, H., Kimura, H., Hatano, S. Y., Suemori, H., Nakatsuji, N., and Tada, T. (2005) Octamer and Sox elements are required for transcriptional cis regulation of Nanog gene expression. *Mol. Cell. Biol.* **25,** 2475–2485
- 24. Das, B., Schreiber, A. M., Huang, H., and Brown, D. D. (2002) Multiple thyroid hormone-induced muscle growth and death programs during metamorphosis in *Xenopus laevis*. *Proc. Natl. Acad. Sci. U.S.A.* **99,** 12230–12235
- 25. Braun, S. (2008) Muscular gene transfer using nonviral vectors. *Curr. Gene. Ther.* **8,** 391–405
- 26. Dueñas-Carrera, S. (2004) DNA vaccination against hepatitis C. *Curr. Opin. Mol. Ther.* **6,** 146–150
- 27. Smith, K. P., Luong, M. X., and Stein, G. S. (2009) Pluripotency: toward a gold standard for human ES and iPS cells. *J. Cell. Physiol.* **220,** 21–29
- 28. Chan, J., and Serluca, F. C. (2004) Chemical approaches to angiogenesis. *Methods Cell Biol.* **76,** 475–487
- 29. Morrison, G. M., and Brickman, J. M. (2006) Conserved roles for Oct4 homologues in maintaining multipotency during early vertebrate development. *Development* **133,** 2011–2022
- 30. Heng, J. C., Orlov, Y. L., and Ng, H. H. (2010) Transcription factors for the modulation of pluripotency and reprogramming. *Cold Spring Harbor Symp. Quant. Biol.* **75,** 237–244
- 31. Liu, N., Lu, M., Tian, X., and Han, Z. (2007) Molecular mechanisms involved in self-renewal and pluripotency of embryonic stem cells. *J. Cell. Physiol.* **211,** 279–286
- 32. Li, R., Liang, J., Ni, S., Zhou, T., Qing, X., Li, H., He, W., Chen, J., Li, F., Zhuang, Q., Qin, B., Xu, J., Li, W., Yang, J., Gan, Y., Qin, D., Feng, S., Song, H., Yang, D., Zhang, B., Zeng, L., Lai, L., Esteban, M. A., and Pei, D. (2010) A mesenchymal-to-epithelial transition initiates and is required for the nuclear reprogramming of mouse fibroblasts. *Cell Stem Cell* **7,** 51–63
- 33. Samavarchi-Tehrani, P., Golipour, A., David, L., Sung, H. K., Beyer, T. A., Datti, A., Woltjen, K., Nagy, A., and Wrana, J. L. (2010) Functional genomics reveals a BMP-driven mesenchymal-to-epithelial transition in the initiation of somatic cell reprogramming. *Cell Stem Cell* **7,** 64–77
- 34. Chambers, I., and Tomlinson, S. R. (2009) The transcriptional foundation of pluripotency. *Development* **136,** 2311–2322
- 35. Papalopulu, N., and Kintner, C. (1996) A *Xenopus* gene, *Xbr-1*, defines a novel class of homeobox genes and is expressed in the dorsal ciliary margin of the eye. *Dev. Biol.* **174,** 104–114
- 36. Cao, Y. Knöchel, S., Donow, C., Miethe, J., Kaufmann, E., and Knöchel, W. (2004) The POU factor Oct-25 regulates the *Xvent-2B* gene and counteracts terminal differentiation in *Xenopus* embryos. *J. Biol. Chem.* **279,** 43735–43743
- 37. Silva, J., Chambers, I., Pollard, S., and Smith, A. (2006) Nanog promotes transfer of pluripotency after cell fusion. *Nature* **441,** 997–1001
- 38. Dixon, J. E., Allegrucci, C., Redwood, C., Kump, K., Bian, Y., Chatfield, J., Chen, Y. H., Sottile, V., Voss, S. R., Alberio, R., and Johnson, A. D. (2010) Axolotl Nanog activity in mouse embryonic stem cells demonstrates that ground state pluripotency is conserved from urodele amphibians to mammals. *Development* **137,** 2973–2980
- 39. Tat, P. A., Sumer, H., Jones, K. L., Upton, K., and Verma, P. J. (2010) The

efficient generation of induced pluripotent stem (iPS) cells from adult mouse adipose tissue-derived and neural stem cells. *Cell Transplant.* **19,** 525–536

- 40. De Carvalho, D. D., You, J. S., and Jones, P. A. (2010) DNA methylation and cellular reprogramming. *Trends Cell Biol.* **20,** 609–617
- 41. Singhal, N., Graumann, J., Wu, G., Araúzo-Bravo, M. J., Han, D. W., Greber, B., Gentile, L., Mann, M., and Schöler, H. R. (2010) Chromatin-remodeling components of the BAF complex facilitate reprogramming. *Cell* **141,** 943–955
- 42. Barreto, G., Schäfer, A., Marhold, J., Stach, D., Swaminathan, S. K., Handa, V., Döderlein, G., Maltry, N., Wu, W., Lyko, F., and Niehrs, C. (2007) Gadd45a promotes epigenetic gene activation by repair-mediated DNA demethylation. *Nature* **445,** 671–675
- 43. Hansis, C., Barreto, G., Maltry, N., and Niehrs, C. (2004) Nuclear reprogramming of human somatic cells by xenopus egg extract requires BRG1. *Curr. Biol.* **14,** 1475–1480
- 44. Albini, S., and Puri, P. L. (2010) SWI/SNF complexes, chromatin remodeling and skeletal myogenesis: it's time to exchange! *Exp. Cell Res.* **316,** 3073–3080
- 45. Huang, J., Wang, F., Okuka, M., Liu, N., Ji, G., Ye, X., Zuo, B., Li, M., Liang, P., Ge, W. W., Tsibris, J. C., Keefe, D. L., and Liu, L. (2011) Association of telomere length with authentic pluripotency of ES/iPS cells. *Cell Res.* **21,** 779–792
- 46. Delaune, E., Lemaire, P., and Kodjabachian, L. (2005) Neural induction in *Xenopus* requires early FGF signalling in addition to BMP inhibition. *Development* **132,** 299–310
- 47. Okabayashi, K., and Asashima, M. (2003) Tissue generation from amphibian animal caps. *Curr. Opin. Genet. Dev.* **13,** 502–507
- 48. Blelloch, R., Wang, Z., Meissner, A., Pollard, S., Smith, A., and Jaenisch, R. (2006) Reprogramming efficiency following somatic cell nuclear transfer is influenced by the differentiation and methylation state of the donor nucleus. *Stem Cells* **24,** 2007–2013
- 49. Hanna, J., Markoulaki, S., Schorderet, P., Carey, B. W., Beard, C., Wernig, M., Creyghton, M. P., Steine, E. J., Cassady, J. P., Foreman, R., Lengner, C. J., Dausman, J. A., and Jaenisch, R. (2008) Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency. *Cell* **133,** 250–264
- 50. Silva, J., Barrandon, O., Nichols, J., Kawaguchi, J., Theunissen, T. W., and Smith, A. (2008) Promotion of reprogramming to ground state pluripotency by signal inhibition. *PLoS Biol.* **6,** e253
- 51. Watanabe, S., Hirai, H., Asakura, Y., Tastad, C., Verma, M., Keller, C., Dutton, J. R., and Asakura, A. (2011) MyoD gene suppression by Oct4 is required for reprogramming in myoblasts to produce induced pluripotent stem cells. *Stem Cells* **29,** 505–516
- 52. Hanna, J., Saha, K., Pando, B., van Zon, J., Lengner, C. J., Creyghton, M. P., van Oudenaarden, A., and Jaenisch, R. (2009) Direct cell reprogramming is a stochastic process amenable to acceleration. *Nature* **462,** 595–601
- 53. Straube, W. L., and Tanaka, E. M. (2006) Reversibility of the differentiated state: regeneration in amphibians. *Artif. Organs* **30,** 743–755
- 54. Kim, J. B., Sebastiano, V., Wu, G., Araúzo-Bravo, M. J., Sasse, P., Gentile, L., Ko, K., Ruau, D., Ehrich, M., van den Boom, D., Meyer, J., Hübner, K., Bernemann, C., Ortmeier, C., Zenke, M., Fleischmann, B. K., Zaehres, H., and Schöler, H. R. (2009) Oct4-induced pluripotency in adult neural stem cells. *Cell* **136,** 411–419
- 55. Jullien, J., Astrand, C., Halley-Stott, R. P., Garrett, N., and Gurdon, J. B. (2010) Characterization of somatic cell nuclear reprogramming by oocytes in which a linker histone is required for pluripotency gene reactivation. *Proc. Natl. Acad. Sci. U.S.A.* **107,** 5483–5488
- 56. Johnson, A. D., Richardson, E., Bachvarova, R. F., and Crother, B. I. (2011) Evolution of the germ line-soma relationship in vertebrate embryos. *Reproduction* **141,** 291–300

